Search results
Showing 331 to 345 of 997 results for death
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation (HTG417)
Evidence-based recommendations on percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation in adults. This involves destroying the tissue causing atrial fibrillation using laser energy.
Fetoscopic prenatal repair for open neural tube defects in the fetus (HTG536)
Evidence-based recommendations on fetoscopic prenatal repair of open neural tube defects in the fetus. This involves keyhole surgery through the woman’s abdomen to close the gap in the baby’s spine.
View recommendations for HTG536Show all sections
Evidence-based recommendations on latanoprost–netarsudil (Roclanda) for previously treated primary open-angle glaucoma or ocular hypertension in adults.
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.
High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)
Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).
This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS22Show all sections
Sections for QS22
- Quality statements
- Quality statement 1: Access to antenatal care
- Quality statement 2: Risk assessment
- Quality statement 3: Continuity of carer
- Quality statement 4: Vaccination
- Quality statement 5: Referral for stop-smoking support and treatment
- Quality statement 6: Healthy eating in pregnancy
- Update information
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.
How you can use our recommendations, tools and resources: maternity and neonatal health
How to use NICE guidance to reduce health inequalities during and after pregnancy.
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
This quality standard covers diagnosing and managing hypertension (high blood pressure) and pre-eclampsia during pregnancy, labour and birth. It also covers advice for women with hypertension who may become pregnant and postnatal care for women who have had hypertension or pre-eclampsia. It describes high-quality care in priority areas for improvement.
View quality statements for QS35Show all sections
Sections for QS35
- Quality statements
- Quality statement 1: Pre-pregnancy advice for women with treated hypertension
- Quality statement 2: Antenatal assessment of pre-eclampsia risk
- Quality statement 3: Antenatal blood pressure targets
- Quality statement 4: Assessing women with severe hypertension in pregnancy
- Quality statement 5: Admission to hospital for women with pre-eclampsia
- Quality statement 6: Timing of birth for women with pre-eclampsia
- Quality statement 7: Transfer of information about ongoing management